<unk>  (trade name Ecclock; development code BBI-4000) is a drug used to treat hyperhidrosis (excessive sweating). It was approved in Japan in 2020 as a 5% gel for the treament of primary axillary hyperhidrosis (PAH).<unk>  is an anticholinergic agent that reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands. It is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium<unk> , meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.
Sofpironium bromide
Ipratropium bromide
Tiotropium bromide
Glycopyrronium bromide
Levosalbutamol
Plerixafor
Pulmocide
Tiotixene